Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 8.25p 8.00p 8.50p 8.25p 8.15p 8.25p 26,871 14:00:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.4 -10.9 -1.3 - 95.85

Tissue Regenix Share Discussion Threads

Showing 9001 to 9023 of 9025 messages
Chat Pages: 361  360  359  358  357  356  355  354  353  352  351  350  Older
DateSubjectAuthorDiscuss
15/11/2017
12:40
Well a 29,150,000 trade at mid price - that should get us a "Holdings" RNS for sure !!
channel pirate
10/11/2017
14:48
Well done for the contact, but, in all honesty, not especially enlightening in terms of the "how". Let's wait and see some genuinely detailed statements of that.
grahamburn
10/11/2017
09:45
Sent an Email to Mr Couldwell (new CEO)and have received a reply, (I feel sure he would not mind me sharing with you all) - see both below Never ever got a reply to emails sent to the company with previous CEO in place !! 03rd November 2017. Dear Mr Couldwell, Congratulations on your appointment of C.E.O. of Tissue Regenix Group plc I look forward to you using your past experience etc in building / guiding the company into a very successful player in the regenerative medical arena as you grow it’s potential. Wishing you every success. Kind Regards, XYZ (shareholder) ................................................................................... 10th November 2017 Dear Mr XYZ, many thanks for your email forwarded to me via Caitlin. I’m excited by the opportunities we have at TRG and look forward to leading the organization to increasing commercial and value creation success Kind Regards Steve Couldwell
channel pirate
06/11/2017
09:16
Igbert, lol. I didn't think trx would join the ranks of aim penny shares. Something newswise had better happen pretty quickly.
bamboo2
02/11/2017
07:16
Buggins turn
igbertsponk
02/11/2017
07:10
02/11/2017 7:00am UK Regulatory (RNS & others) Tissue Regenix (LSE:TRX) Intraday Stock Chart Today : Thursday 2 November 2017 Click Here for more Tissue Regenix Charts. TIDMTRX RNS Number : 3338V Tissue Regenix Group PLC 02 November 2017 Tissue Regenix Group plc Appointment of CEO Steve Couldwell appointed Group CEO Leeds, 02 November 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces the appointment of Steve Couldwell, as Chief Executive Officer of the Group, effective immediately. Steve has been in the position of non- executive director since July 2013. Steve has over 25 years' experience in the pharmaceutical and medical device industry and a proven track record of delivering revenue and profit growth. Most recently Steve was Chief Operating Officer - Global Sanofi Biosurgery, with responsibility for strategy and execution for global business including manufacturing, regulatory, medical affairs and marketing/ commercial execution, delivering strong double digit growth internationally for 3 consecutive years. Prior to this Steve held a number of roles at Smith & Nephew including President, Orthopaedics, Europe and Senior VP Sales and Marketing of the Advanced Wound Management business. Steve Couldwell, Tissue Regenix incoming CEO commented: "Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7bn[1] US bone graft and substitute market. I am delighted to be appointed CEO and look forward to leading the Group through the integration of CellRight and expansion of commercial activities as we execute our commercial strategy and grow our market share throughout the US and the rest of the world." John Samuel, Chairman, Tissue Regenix: "The Board and I are delighted to welcome Steve as the Group's new CEO. He has an exceptional track record of growing businesses and the Board firmly believes that Steve has the required skillset and experience to guide the Group along the pathway to profitability. Alongside this, Steve has an in-depth knowledge of the Group thanks to his years as a non-executive director making him an ideal candidate for this position." Additional information on Mr Couldwell The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies: Current and past Directorships and Partnerships for Steve Couldwell within the last 5 years, aged 57: Current -- Tissue Regenix Group plc -- Zilico There is no further information required to be disclosed pursuant to Schedule 2(g) of the AIM Rules. For more Information:
channel pirate
31/10/2017
18:48
Any news on appointment yet
swiss paul
28/10/2017
18:47
From the RNS 20th July 2017............... ............Tissue Regenix also announces its intention to raise gross proceeds of approximately GBP40 million pursuant to a placing of up to 400 million new Ordinary Shares less the number of any Subscription Shares (as defined below) (the "Placing Shares") in the Company at a price of 10 pence per Placing Share, with both new and existing institutional investors (the "Placing"). I wonder how those "new and existing institutional investors" are feeling with their discounted privileged investments now, seeing Mr Small pi buying as low as 8.15p on Friday just gone ?
channel pirate
27/10/2017
15:29
where is everyone when the share price 8pc down?
ali47fish
18/10/2017
12:41
So Odell won’t be at the presentation then. Wonder who will? Some mighty tough questions for whoever it is! Urrm, why are you doing this? I don’t know...Woodford said he had to go..and go he did...
rayrac
18/10/2017
10:25
Just got this, think it may change! "Good morning, You are warmly invited to attend Proactive Investors' One2One Healthcare Forum which is taking place on Thursday 2nd November at The Chesterfield Mayfair Hotel from 6pm. Presenting on the evening will be ImmuPharma (LON:IMM), Widecells (LON:WDC), Synairgen (LON:SDX) & Tissue Regenix (LON:TRX). To register to attend please click on the panel to the right or reply to this email. ImmuPharma (LON:IMM - Market Cap: £131 Million) ... Widecells (LON:WDC Market Cap: £9 Million) .... Tissue Regenix (LON:TRX - Market Cap: £106 Million) Tissue Regenix is a leading medical devices in the field of regenerative medicine. The company's patented dCELL technology removes DNA and other cellular material from animal and human soft tissue leaving a cellular tissue scaffold. Current applications address many critical clinical needs such as sport medicine, heart valve replacement and wound care. CEO Anthony Odell will be at the forum to present to investors and answer any questions on the company.
igbertsponk
18/10/2017
09:04
Well at the moment it looks like the market hasn't seen the departure of Antony Odell as a big negative as the share price hasn't moved - and to buy is only 0.068 of a penny cheaper than yesterday. (delayed reaction !! so now they bring the share price down later in the morning / afternoon)
channel pirate
18/10/2017
07:38
Well, it obviously isnt a health issue for the departing ceo! All seems rather strange to me, perhaps Woodford wasn't keen on the performance and wanted him out? Whatever, it smells!
rayrac
18/10/2017
06:16
Yes, time some new blood given a go.
igbertsponk
18/10/2017
06:13
18/10/2017 7:00am UK Regulatory (RNS & others) Tissue Regenix (LSE:TRX) Intraday Stock Chart Today : Wednesday 18 October 2017 Click Here for more Tissue Regenix Charts. TIDMTRX RNS Number : 8786T Tissue Regenix Group PLC 18 October 2017 [This announcement contains inside information.] Tissue Regenix Group plc Directorate Change Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") today announces that Antony Odell, Chief Executive Officer (CEO), will be stepping down from his role and position on the Board with immediate effect. The Board will commence a process for appointment of a new CEO. In the interim, John Samuel, Non- Executive Chairman has assumed the role of Executive Chairman. John Samuel, Executive Chairman Tissue Regenix Group, commented: "The Board of Directors and I would like to thank Antony for his dedication and commitment to Tissue Regenix since he was appointed CEO in 2008. He has been a key member of the executive team. During his tenure the Company has listed on the AIM market, successfully commercialised products in the US and earlier this year completed the transformational acquisition of CellRight, while continuing to pursue additional commercial opportunities. We wish him every success in his future career." The integration of CellRight continues as planned and current trading remains in line with Board expectations.
channel pirate
13/10/2017
11:07
The product is great (in theory, as I have no practical knowledge) yet the company is not, it seems. These small spin-off businesses are speculative buys as there are so many factors that determine their success, not just the product. I'm long, and have been for a while, and I'm going to watch closely for a sign either way: if we're not above 15p by the New Year, then I'll reduce, as I will if we drop under 10p. Maybe Warren had better rephrase his remark about companies run by monkeys, and replace the animal with pigs, in this case. Trouble is, this business needs better management, IMHO.
andrewbaker
11/10/2017
13:30
That's about 1.4 mil shares dumped at 10.5 over the last few days, not awe inspiring.
alphapig
11/10/2017
06:59
Wed, 11th Oct 2017 07:15 RNS Number : 2491T Tissue Regenix Group PLC 11 October 2017 Hardman Research: Dual revenue stream growth Dual revenue stream growth - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has been on expanding in the US wound care and orthopaedic markets: in August 2017, TRX acquired CellRight Technologies, bringing in synergistic bone regeneration technology. FY'17 results will be the first to reflect the acquisition and will include 5 months of the enlarged entity. The 1H'17 results presented here are for stand-alone TRX, and show organic growth, both from the EU jv and from DermaPure, to a £1.38m total. Please click here for the full report: hxxp://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/11.10.17-dual-revenue-stream-growth.pdf
channel pirate
29/9/2017
18:45
Hi Bamboo2... In biotech and related spheres (other than major pharma), you get the best stock and company exposure with funds rather than specific companies and also limits downside risks. Early stage companies in this field are effectively are a "all or none phenomenon" - bust more often than not. The challenge of commercialisation with all the regulatory hurdles and often having to be duplicated in different countries, pharmaco-economic analysis costs and the odd adverse event put paid to a number of prospective candidates. Good luck all :)
multibagger
29/9/2017
16:26
Cheers channel pirate and mb, This seems a classic case of great idea, but hard to monetise. Particularly in the UK. Meniscus/tendon/cartilage off the shelf looks fantastic, but without a current CE mark, it is going nowhere. Xenografts have a great future, but my bet is that it will take one of the bigger pharmas in partnership or buyout to get these products to market.
bamboo2
29/9/2017
11:35
multibagger11 Jul '14 - 08:15 - 947 of 2011 0 0 Edit Hi Bamboo2.....as I have posted sometime ago the NHS is hardly the fastest adopter of new technology. The procurement process and bureaucratic hurdles test the patience of saints and I am not at all surprised by the information vacuum. Adoption of new tech is largely down to local factors. Contrary to what many would expect, the NHS remains a patchwork of hospitals, CCGS with varying agendas, priorities and vision - there is no consistent approach to clinical issues (management and governance structures are slightly more consistent due to regulatory mechanisms). What I would expect is a drip - drip of occasional contracts from the NHS - not an unified master contract. If anything better comes off, I would be delighted. I have made good profits from TRX and taken them, so what is riding here is effectively free. My investment take on TRX is on the premise that they are / will be an attractive takeover candidate for a bigger pharma. It would be interesting to see how the US commercialisation takes off. TRX are in the right field at the right time, but as I have mentioned I do not see their tech as being cutting edge. In a rapidly evolving field of regenerative medicine, they seem to holding onto "obsolete" low cost barrier tech....unless they are working on something very secretly ! Also after attending the AGM last year, I got the impression that communication is not the strength of the leadership team - further confirmed that my some recent emails which have been ignored. I am not as excited as I once was and my take is probably also coloured by the fact that I have taken profits after re-assessing the overall situation. Good luck all :)
multibagger
29/9/2017
11:28
Hi Bamboo2...good to see that you are out of this and I recall saying about 2-3 years ago that the TRX does not have enough cutting edge R&D and also commercialisation is going to be a huge challenge. So I am not surprised at all. I also did not like the attitude of senior directors who did not have the courtesy to reply to emails. I attended one AGM and then made up my mind to get out. Good luck to whoever chooses to stay in or is locked in - Neil Woodford included !!
multibagger
29/9/2017
09:35
Sorry to hear you have emptied your pot of TRX shares, but as said before, you have to go with your own gut feelings. I to am disappointed at the company (not only this company) changing direction a bit, after all, we invest after doing our research and listening / looking at what news the company has furnished "Mr Joe public" with in order to attract our support (us buying shares). I am hoping we have come to rest here somewhere near the bottom, so will hang in there for a time and hope for the best. Good Luck bamboo2
channel pirate
Chat Pages: 361  360  359  358  357  356  355  354  353  352  351  350  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171120 19:27:46